Literature DB >> 11728978

Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1.

P Hovind1, L Tarnow, P Rossing, T Teerlink, C D Stehouwer, J J Emeis, H H Parving.   

Abstract

Among patients with diabetic nephropathy, the decline in glomerular filtration rate (GFR) varies substantially, ranging from 2 to 20 mL/min per year. Identification of predictors of progression in diabetic nephropathy is important. Plasma total homocysteine (tHcy) rises with urinary albumin excretion rate in diabetes, and plasminogen activator inhibitor-1 (PAI-1) has been correlated with increased matrix accumulation in various glomerulopathies. In this prospective observational cohort study, we evaluated the importance of baseline tHcy and PAI-1 as predictors of the rate of decline in GFR. Baseline tHcy and PAI-1 were measured in 157 type 1 diabetic patients with diabetic nephropathy (92 men; mean age, 41 +/- 10 years; mean diabetes duration, 27 +/- 8 years; median GFR, 80 mL/min/1.73 m(2) [range, 23 to 143 mL/min/1.73 m(2)]). Hereafter, GFR was measured yearly with a plasma clearance technique for at least 3 years (median, 7 years [range, 3.0 to 8.3 years]). The mean rate of decline in GFR was 3.7 +/- 0.3 mL/min per year. A linear regression analysis revealed a borderline significant relationship between rate of decline in GFR and tHcy (P = 0.069) and PAI-1 (P = 0.087). Analysis of the rate of decline in GFR and tertiles of tHcy and PAI-1 revealed that increasing levels of tHcy were correlated with a significantly faster decline in GFR (P = 0.025), whereas increasing levels of PAI-1 were not. After adjustment for other well-established risk factors for progression of nephropathy in a multiple linear regression analysis, however, neither tHcy levels nor PAI-1 levels were independent predictors of rate of decline in GFR.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11728978     DOI: 10.1053/ajkd.2001.29261

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  5 in total

1.  Association between plasma homocysteine and progression of early nephropathy in type 2 diabetic patients.

Authors:  Huan Wang; Kai Cui; Ke Xu; Shixin Xu
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Plasma homocysteine is adversely associated with glomerular filtration rate in asymptomatic black and white young adults: the Bogalusa heart study.

Authors:  Litao Ruan; Wei Chen; Sathanur R Srinivasan; Jihua Xu; Ahmet Toprak; Gerald S Berenson
Journal:  Eur J Epidemiol       Date:  2009-04-25       Impact factor: 8.082

3.  Genetically elevated circulating homocysteine concentrations increase the risk of diabetic kidney disease in Chinese diabetic patients.

Authors:  Liang Ma; Qian Liu; Yongwei Jiang; Hailing Zhao; Tingting Zhao; Yongtong Cao; Ping Li; Wenquan Niu
Journal:  J Cell Mol Med       Date:  2019-02-07       Impact factor: 5.310

4.  The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease.

Authors:  Robert G Fassett; Madeleine J Ball; Iain K Robertson; Dominic P Geraghty; Jeff S Coombes
Journal:  BMC Nephrol       Date:  2008-03-18       Impact factor: 2.388

5.  Hyperhomocysteinemia Causes Chorioretinal Angiogenesis with Placental Growth Factor Upregulation.

Authors:  Yih-Jing Lee; Chia-Ying Ke; Ni Tien; Po-Kang Lin
Journal:  Sci Rep       Date:  2018-10-25       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.